Pipeline

The following table shows our most advanced programs and their stage in the drug discover and development process.

-->
Compound Mechanism of Action Indications Status
NT-113 Irreversible pan-erbB Inhibitor Glioblastoma
Non-small Cell Lung Cancer
Head & Neck Cancer
Phase 1 study to initiate 2017
UCSF collaboration in glioblastoma
NT-004 Reversible pan-erbB Inhibitor Breast Cancer
Other Solid Tumors
Phase 1 study to initiate 2018
NT-125 PARP Inhibitor Ovarian Cancer
Breast Cancer
Phase 1 study to initiate 2018

 

NT-113: Irreversible Pan-erbB Inhibitor
The erbB receptors, epidermal growth factor (EGFR, erbB1), HER2 (erbB2), erbB3 and erbB4 work in concert to transmit signals across cell membranes controlling a variety of cellular functions including cell growth, proliferation, differentiation and migration. Several agents binding to single erbB receptors have been approved including erlotinib and gefitinib. Our strategy is to discover and develop agents that cross the blood brain barrier and irreversibly inhibit multiple erbB receptors including EGFR, HER2 and HER4, thereby interfering with the cooperation that exists between receptors. NT-113, is a potent irreversible pan-erbB inhibitor that crosses the blood brain barrier, has shown superior anti-cancer activity in vivo when compared to other agents in clinical development and is active against important EGFR mutations including T790M, L858R and T790M/L858R. NT-113 has also shown potent anti-cancer activity in multiple intracranial mouse xenograft models using human glioblastoma cell lines with the disease driving EGFRvIII mutation or that overexpress EGFR.

NT-004: Reversible Pan-erbB Inhibitor
The erbB receptors, epidermal growth factor (EGFR, erbB1), HER2 (erbB2), erbB3 and erbB4 work in concert to transmit signals across cell membranes controlling a variety of cellular functions including cell growth, proliferation, differentiation and migration. Mutations and amplification of the erbB family as well as overexpression of the erbB receptors and or ligands have been associated with late stage cancers including lung, breast, gastric, head & neck, and colon cancer. Our oral lead compound has shown equivalent to superior in vitro and in vivo anti-cancer activity when compared to other agents in clinical development.

NT-125: PARP Inhibitor
A next generation poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of solid tumors that combines several favorable properties including high potency, single agent and combination chemotherapeutic activity, superior PK and oral bioavailability.

 

 

-->

NEWS & EVENTS

8/10/2015: NewGen Granted Composition of Matter patent for NT-113


CONTACT INFORMATION

Corporate Headquarters:
3475 Edison Way, Suite R
Menlo Park, CA 94025
+1.650.995.7508